This CPB has been revised to state that golimumab (Simponi Aria) is considered medically necessary for active articular juvenile idiopathic arthritis when criteria are met. To align with CVS/Caremark, the TB statement and criteria nomenclature were updated, and a note was added to the dosing recommendations section stating "Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines".